Shopping Cart
- Remove All
- Your shopping cart is currently empty
Tisagenlecleucel (CTL019), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, selectively targets and eradicates CD19-expressing B cells, and is utilized in the study of refractory aggressive diffuse large B-cell lymphoma [1] [2].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | Tisagenlecleucel (CTL019), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, selectively targets and eradicates CD19-expressing B cells, and is utilized in the study of refractory aggressive diffuse large B-cell lymphoma [1] [2]. |
In vivo | Tisagenlecleucel targets and eliminates B cells expressing CD19, demonstrating efficacy against B-cell lymphoma [1]. |
Alias | CTL019 |
Cas No. | 1823078-37-0 |
Storage | keep away from moisture | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.